On September 15, the FDA authorized GSK’s oral medication momelotinib, now known as Ojjaara, for the treatment of myelofibrosis in adults with anemia. Myelofibrosis is a disorder where normal bone marrow tissue is slowly substituted by fibrous, scar-like material. It is categorized as a form of chronic leukemia and is grouped within myeloproliferative diseases, ultimately leading to the gradual deterioration of bone marrow function.
As per DelveInsight analysis, the total prevalent population of myelofibrosis in the 7MM comprised approximately 40K cases in 2022 and is projected to increase during the study period (2019–2032). As per the estimates, in 2022, the high...
